AI Terminal
N4 PHARMA PLC
Director's Dealing • Feb 6, 2025
7804_rns_2025-02-06_f540f226-16b9-46a8-a73f-4e559547197b.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2342W
Ananda Pharma PLC
06 February 2025
06 February 2025
ANANDA PHARMA PLC
("Ananda" or the "Company")
Director/PDMR Shareholding
Ananda announces that on 06 February 2025, Melissa Sturgess, the Company's Chief Executive Officer, purchased 5,000,000 ordinary shares of 0.2p each in the Company ("Ordinary Shares") at a price of 0.43p per Ordinary Share.
After this transaction, Melissa Sturgess has a beneficial interest in 427,382,284 Ordinary Shares, representing 10.04% of the issued share capital of Ananda.
About Ananda Pharma
Ananda Pharma (AQSE: ANA), is a UK-based developer of licenced, cannabinoid medicines targeting the treatment of complex, chronic conditions. The Company is led by successful entrepreneurs and a team of world-class scientists.
For more information, please visit: www.anandapharma.co.uk
To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn : https://www.linkedin.com/company/anandapharma
· X : https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
| ANANDA PHARMA PLC | +44 (0)7463 686 497 |
| [email protected] | |
| Chief Executive Officer | |
| Melissa Sturgess | |
| Finance Director | |
| Jeremy Sturgess-Smith | |
| SP ANGEL CORPORATE FINANCE LLP | +44 (0)20 3470 0470 |
| Corporate Finance | |
| Richard Morrison | |
| Corporate Broking | |
| Abigail Wayne | |
| Rob Rees | |
| Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 [email protected] |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. | ||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Melissa Sturgess |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Ananda Pharma plc |
| b) | LEI | 894500DFM8VOC5FW4X47 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares ISIN: GB00BDQPXQ60 |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | 5,000,000 Ordinary Shares at 0.43p per share |
| d) | Aggregated information - Aggregated volume - Price |
N/A |
| e) | Date of the transaction | 06 February 2025 |
| f) | Place of the transaction | Off Market |
https://investors.anandapharma.co.uk/link/pegKZe
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXBUGDDSGGDGUL